https://www.eurekalert.org/news-releases/928743
News Release 16-Sep-2021
Research from Penn Medicine shows mRNA COVID-19 vaccines are effective at inducing T-cell responses in multiple sclerosis patients who receive B cell-depleting infusions even if their antibody responses are diminished
Peer-Reviewed Publication
University of Pennsylvania School of Medicine
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.
Because B cells are responsible for antibody production, patients’ ability to produce antibodies that prevent the virus from entering and infecting a person’s cells is significantly muted when the B cells are depleted with aCD20 treatment. But the same patients are nonetheless able to mount very good responses of the second protective arm of their immune system, which uses T cells to eliminate cells once infected (thereby preventing viral spread to other cells), according to new research from the Perelman School of Medicine at the University of Pennsylvania in a new paper published in Nature Medicine.
-----
No comments:
Post a Comment